Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 7Ovarian Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Penile Neoplasms 1Pelvic Neoplasms 1Metastatic Solid Tumors 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1Advanced Solid Tumors 1

Interventions

Injections 27Carboplatin 18Docetaxel 14pembrolizumab 13Paclitaxel 12Bevacizumab 10durvalumab 8Nivolumab 8Cisplatin 8Fluorouracil 7Pemetrexed 6Oxaliplatin 6Leucovorin 6trifluridine tipiracil drug combination 5toripalimab 5tislelizumab 5linifanib 5Capecitabine 5zimberelimab 4talazoparib 4olaparib 4fludarabine 4Panobinostat 4Itraconazole 4Irinotecan 4Gemcitabine 4Everolimus 4tremelimumab 3sotorasib 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × Platinum × Other solid neoplasm × Clear all
NCT06394414 2025-02-24

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1 Recruiting
162 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡